Heron Therapeutics

Historical price data

Heron Therapeutics is a fully integrated biopharmaceutical company with a mission to improve patient lives through best-in-class, non-opioid medicines. The company has successfully commercialized a portfolio of four products targeting postoperative pain (ZYNRELEF®) and nausea/vomiting (SUSTOL®, CINVANTI®, APONVIE®), leveraging its proprietary Biochronomer® drug delivery technology to create sustained-release formulations. Its strategy focuses on addressing significant unmet needs in acute and oncology care by providing long-duration, localized therapy from a single administration, thereby reducing systemic side effects and healthcare burdens associated with opioid use and uncontrolled symptoms.

Biochronomer® polymer-based drug delivery platform for sustained, localized release of therapeutics over days to weeks from a single injection.

Heron competes in crowded markets: ZYNRELEF® faces off against generic opioids and branded long-acting local anesthetics, while its antiemetics compete with a wide array of generic and branded 5-HT3 and NK-1 antagonists. Its differentiation stems from delivery technology enabling prolonged effect or rapid administration.